Vicore Pharma Holding ABVCRE -4.00%13 Cash Ratio is 12.52 as of Mar. 2026, which is 14% above its 10-year median of 10.94. GuruFocus rates VCRE with a GF Score™ of 13/100. The stock has 5 warning signs investors should review. Among 1,387 Biotechnology companies, Vicore Pharma Holding AB ranks better than 85.08% on this metric.
Vicore Pharma Holding AB has a Cash Ratio of 12.52. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Vicore Pharma Holding AB's Cash Ratio or its related term are showing as below:
VCRE'
s Cash Ratio Range Over the Past 10 Years
Min: 0.94 Med: 10.94 Max: 23.54
Current: 12.52
During the past 13 years, Vicore Pharma Holding AB's highest Cash Ratio was 23.54. The lowest was 0.94. And the median was 10.94.
VCRE's Cash Ratio is ranked better than 85.08% of 1387
companies
in the Biotechnology industry
Industry Median: 2.93
vs VCRE: 12.52
Vicore Pharma Holding AB (NAS:VCRE) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Vicore Pharma Holding AB Cash Ratio Related Terms
Vicore Pharma Holding AB Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vicore Pharma Holding AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vicore Pharma Holding AB Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Vicore Pharma Holding AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vicore Pharma Holding AB (VCRE) has a Cash Ratio of 12.52 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Vicore Pharma Holding AB and its competitors. This is 14% above median its historical median of 10.94. Over the past decade, Vicore Pharma Holding AB's Cash Ratio has ranged from 0.94 to 23.54. According to the industry distribution chart, Vicore Pharma Holding AB ranks #207 out of 1387 companies in the Biotechnology industry, placing it in the top 14.9%.
Is Vicore Pharma Holding AB's Cash Ratio too high?
Vicore Pharma Holding AB's current Cash Ratio of 12.52 is 14% above median its 10-year median of 10.94. Over the past 10 years, this metric has ranged from a low of 0.94 to a high of 23.54. The Biotechnology industry median Cash Ratio is 2.93. Vicore Pharma Holding AB's value of 12.52 is 327.3% above this industry median. Based on the distribution chart, Vicore Pharma Holding AB ranks #207 out of 1387 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vicore Pharma Holding AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Vicore Pharma Holding AB's Cash Ratio compare to ?
According to the Biotechnology industry distribution chart, Vicore Pharma Holding AB ranks #207 out of 1387 companies for Cash Ratio. This places Vicore Pharma Holding AB in the top 15% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. Vicore Pharma Holding AB's value of 12.52 is 327.3% above this benchmark. Historically, Vicore Pharma Holding AB's own Cash Ratio has ranged from 0.94 to 23.54 over the past decade. While the company's 10-year median is 10.94 vs. the industry median of 2.93, Vicore Pharma Holding AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,387 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vicore Pharma Holding AB's current Cash Ratio of 12.52 is 327.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Vicore Pharma Holding AB and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vicore Pharma Holding AB's current Cash Ratio is 12.52, which is 14% above median its own 10-year median of 10.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicore Pharma Holding AB stock overvalued right now?
Vicore Pharma Holding AB (VCRE) has a current Cash Ratio of 12.52. The current Cash Ratio is 12.52, which is 14% above median its 10-year median of 10.94 and 327.3% above the Biotechnology industry median of 2.93. Vicore Pharma Holding AB's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Vicore Pharma Holding AB (VCRE), the current Cash Ratio is 12.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
13GF Score
Get the complete analysis for VCRE
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCRE has been successfully added to your 
